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Supplemental Fig. 1. Cation-π binding plot for TyrA, in which          
log[EC50(mutant)/EC50(wt)] is plotted versus quantitative cation-π binding 
energies (Lummis et al., 2005; Zhong et al., 1998); a strong linear correlation 





 Supplemental Fig. 2. Cation-π binding plot for TyrC2, in which                           
log[EC50(mutant)/EC50(wt)] is plotted versus quantitative cation-π binding 
energies (Lummis et al., 2005; Zhong et al., 1998); a strong linear correlation 
would suggest a cation-π interaction.  3-F1-Phe and 4-F1-Phe (open circles) are 
not included in the fit. 
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 Supplemental Table 1. Wild type and principal face mutations.  EC50 and Hill 
coefficient (nH) are ± SEM for goodness of fit to the Hill equation. 
Mutation Agonist EC50 (µM) Fold Shift nH n 
wt ACh 99 ± 3  2.7 ± 0.2 16 
wt Varenicline 1.99 ± 0.03  2.8 ± 0.1 15 
wt Epibatidine 0.34 ± 0.01  3.0 ± 0.2 13 
      
Y93 Tyr Varenicline 2.21 ± 0.05  3.0 ± 0.2 7 
Y93 Phe Varenicline 126 ± 5 57 2.4 ± 0.2 9 
Y93 4-F1-Phe Varenicline 34 ± 3 15 2.0 ± 0.3 11 
Y93 F2-Phe Varenicline >100   8 
Y93 F3-Phe Varenicline >100   8 
Y93 4-Br-Phe Varenicline 12 ± 1 5.4 3.1 ± 0.6 7 
Y93 4-CN-Phe Varenicline 33 ± 2 15 2.5 ± 0.4 10 
Y93 4-MeO-Phe Varenicline 2.19 ± 0.05 0.99 2.3 ± 0.1 6 
      
W149 Trp Varenicline 2.5 ± 0.1  2.1 ± 0.1 17 
W149 F3-Trp Varenicline 4.1 ± 0.1 1.6 2.3 ± 0.1 15 
W149 F4-Trp Varenicline 9.6 ± 0.8 3.8 2.0 ± 0.2 15 
W149 5-CN-Trp Varenicline 2.1 ± 0.1 0.84 2.6 ± 0.4 12 
      
Y188 Tyr Varenicline 2.23 ± 0.08  2.4 ± 0.2 8 
Y188 Phe Varenicline >100   6 
      
Y195 Tyr Varenicline 2.12 ± 0.02  2.76 ± 0.06 8 
Y195 Phe Varenicline 2.28 ± 0.09 1.1 3.1 ± 0.4 6 
Y195 3-F1-Phe Varenicline 5.1 ± 0.07 2.4 1.9 ± 0.02 12 
Y195 4-F1-Phe Varenicline 1.53 ± 0.05 0.72 3.4 ± 0.3 9 
Y195 F2-Phe Varenicline 16.3 ± 0.7 7.7 2.4 ± 0.2 12 
Y195 F3-Phe Varenicline 16 ± 1 7.5 2.6 ± 0.3 7 
Y195 4-Br-Phe Varenicline 3.48 ± 0.07 1.6 3.6 ± 0.2 5 
Y195 4-CN-Phe Varenicline 21 ± 1 9.9 3.8 ± 0.9 11 
Y195 4-MeO-Phe Varenicline 2.42 ± 0.09 1.1 2.8 ± 0.3 11 
      
S150 Thr Varenicline 0.81 ± 0.04  2.2 ± 0.2 11 
S150 Tah Varenicline 2.4 ± 0.1 3.0 from Thr 2.2 ± 0.2 15 
      
K145A ACh N.R.    
K145Q ACh 590 ± 20 6.0 2.5 ± 0.1 8 
K145Q Varenicline 9.4 ± 0.2 4.7 1.6 ± 0.2 7 
K145R ACh 1600 ± 100 16 2.6 ± 0.3 6 
K145R Varenicline 61.6 ± 0.2 31 3.19 ± 0.03 9 
 Supplemental Table 2. Complementary face mutations.  EC50 and Hill 





Mutation Agonist EC50 (µM) Fold Shift nH n 
V108 Val ACh 103 ± 2  2.9 ± 0.2 10 
V108 Vah ACh 184 ± 9 1.8 2.3 ± 0.2 10 
V108 Val Varenicline 2.3 ± 0.1  4 ± 1 8 
V108 Vah Varenicline 10.0 ± 0.5 4.3 2.5 ± 0.3 9 
V108 Val Epibatidine 0.396 ± 0.005  3.02 ± 0.09 7 
V108 Vah Epibatidine 0.64 ± 0.04 1.6 3.4 ± 0.5 11 
L119 Leu ACh 120 ± 6  2.5 ± 0.3 9 
L119 Lah ACh 180 ± 8 1.5 2.4 ± 0.2 6 
L119 Leu Varenicline 2.26 ± 0.02  2.76 ± 0.05 7 
L119 Lah Varenicline 3.15 ± 0.08 1.4 2.2 ± 0.1 9 
L119 Leu Epibatidine 0.290 ± 0.005  3.3 ± 0.1 8 
L119 Lah Epibatidine 0.75 ± 0.01 2.6 3.4 ± 0.1 10 
      
N107L ACh 350 ± 3 3.5 2.48 ± 0.05 5 
N107L Varenicline 2.77 ± 0.05 1.4 2.6 ± 0.1 4 
N107L Epibatidine 1.37 ± 0.02 4.0 2.44 ± 0.06 4 
      
W55A ACh 134 ± 8 1.4 1.9 ± 0.2 8 
W55A Varenicline 67.6 ± 0.9 34 2.95 ± 0.09 11 
W55A Epibatidine 5.8 ± 0.3 17 2.2 ± 0.2 10 
L109A ACh 303 ± 7 3.1 2.4 ± 0.1 9 
L109A Varenicline 0.53 ± 0.01 0.27 3.3 ± 0.2 12 
L109A Epibatidine 0.282 ± 0.008 0.83 2.8 ± 0.2 9 
Q117A ACh 180 ± 4 1.8 2.7 ± 0.1 10 
Q117A Varenicline 4.85 ± 0.06 2.4 2.88 ± 0.09 12 
Q117A Epibatidine 0.90 ± 0.05 2.6 3.0 ± 0.4 11 
L119A ACh 210 ± 9 2.1 2.3 ± 0.2 11 
L119A Varenicline 41 ± 1 21 2.6 ± 0.2 11 
L119A Epibatidine 3.20 ± 0.09 9 3.0 ± 0.2 10 
